Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Flagrante Delictu who wrote (13527)	1/20/1998 2:16:00 PM
From: Andrew H	Respond to of 32384

Ok, thanks Bernie.

To: Flagrante Delictu who wrote (13527)	1/20/1998 2:19:00 PM
From: Henry Niman	Respond to of 32384

CNBC just did another report. This was by Mariola Hagger of Deutsche Morgan Grenfel. She also expected the merger to happen with one driving force being cost cutting. She wouldn't give a price, but thought that AHP was still cheap, even after today's run-up. She indicated that it was trading at a 22% premium to the S&P, while the sector was trading at a 51% premium. Although Pharmas have beat the market for the past 4 years, she expected the sector to continue heading north. She thought that a successful merger would force medium and small pharmas to consider mergers to attract foreign investments, which tend to go to the larger leaders in the sector. Her #1 pick was MRK and they were just added to the US Focus list. She alos liked BMY, SGP, PFE (long term pipeline), and PNU (long term value).